MedTrace Logo

Divalproex Sodium in the Treatment of PTSD (Post-Traumatic Stress Disorder)

NCT00108576 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2015-10-21

No results posted yet for this study

Summary

The purposes of this study are:

* To study the efficacy of divalproex in the treatment of PTSD;
* To study the plasma GABA (gamma aminobutyric acid) levels before and after treatment with divalproex in PTSD.

Conditions

Interventions

DRUG

Divalproex

anticonvulsant; mood stabilizer

OTHER

placebo

Look-a-like placebo

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Lori Lynne Davis, MD AB · Tuscaloosa VA Medical Center, Tuscaloosa, AL

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2005-08-31
Completion
2005-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00108576 on ClinicalTrials.gov